外用抗菌肽omiganan可恢复皮肤菌群失调但未改善轻中度特应性皮炎症状:一项2期随机对照试验
结果显示各omiganan组均恢复菌群失调并减少金黄色葡萄球菌,但未观察到显著临床改善。
要点
- omiganan可减少金黄色葡萄球菌丰度并增加菌群多样性。
- omiganan 2.5%组较溶媒显著减少培养金黄色葡萄球菌(-93.5%)。
- 选择性靶向微生物组的单一治疗未改善轻中度特应性皮炎症状。
核心结论
- 轻中度特应性皮炎患者外用omiganan每日两次至28天可恢复菌群失调,但无临床改善。
主要发现
- 所有omiganan治疗组均通过减少葡萄球菌属丰度并增加多样性恢复菌群失调。
- 未观察到显著临床改善。
临床怎么用
- 选择性靶向微生物组的单一治疗在轻中度特应性皮炎中可能不是成功的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dysbiosis and colonization with Staphylococcus aureus is considered to play an important role in the pathogenesis of atopic dermatitis (AD). Recovering this dysbiosis may improve AD symptoms. Omiganan is a synthetic indolicidin analogue antimicrobial peptide with activity against S aureus and could be a viable new treatment option for AD. OBJECTIVE: To explore the tolerability, clinical efficacy, and pharmacodynamics of omiganan in mild to moderate AD. METHODS: Eighty patients were randomized to omiganan 1%, 1.75%, or 2.5% or vehicle twice daily for 28 days on all lesions. Weekly visits included clinical scores and microbiological and pharmacodynamic assessments of 1 target lesion. RESULTS: In all omiganan treatment groups, dysbiosis was recovered by reducing Staphylococcus species abundance and increasing diversity. A reduction of cultured S aureus was observed in all omiganan treatment groups, with a significant reduction for omiganan 2.5% compared to vehicle (-93.5%; 95% CI, -99.2 to -28.5%; P = .02). No significant clinical improvement was observed. CONCLUSION: Topical administration of omiganan twice daily for up to 28 days in patients with mild to moderate AD led to a recovery of dysbiosis but without clinical improvement. Therefore, a monotreatment that selectively targets the microbiome does not appear to be a successful treatment strategy in mild to moderate AD.
引用
- Niemeyer-van der Kolk T, Buters TP, Krouwels L, et al. Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial. J Am Acad Dermatol. 2020. PMID: 33010325. doi:10.1016/j.jaad.2020.08.132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。